Zobrazeno 1 - 10
of 437
pro vyhledávání: '"Kwee, Yong"'
Autor:
Dario Melotti, Samir Asher, Ethan Troy‐Barnes, George Nesr, William Wilson, Marquita Camilleri, Rakesh Popat, Ke Xu, Neil Rabin, Jonathan Sive, Xenofon Papanikolaou, Lydia Lee, Annabel McMillan, Kwee Yong, Chara Kyriakou
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 1102-1106 (2024)
Abstract High‐dose melphalan followed by stem cell rescue is the standard consolidative therapy for transplant‐eligible patients with multiple myeloma (MM) in the United Kingdom. A melphalan dose of 200 mg/m2 (Mel200) is considered the “gold st
Externí odkaz:
https://doaj.org/article/581d36a722744a3dab5a4e35b207341f
Autor:
Ke Xu, Eleanor Kaffo, Robert Baker, Elisabeth Nacheva, Annabel McMillan, Lydia Lee, Xenofon Papanikolaou, Rakesh Popat, Jonathan Sive, Kwee Yong, Neil Rabin, Charalampia Kyriakou, Rajeev Gupta
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 1089-1091 (2024)
Externí odkaz:
https://doaj.org/article/352a9b0bdfe94b738304d87814fb5ef3
Autor:
Catherine Lecat, Eileen M Boyle, Daniel Hughes, Lydia Lee, Dean Smith, Ceri Bygrave, Karthik Ramasamy, Kwee Yong
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 418-420 (2024)
Externí odkaz:
https://doaj.org/article/48189d4f07f749bfb8fbbe5d6bd7c380
Autor:
Daria Galas-Filipowicz, Selina J. Chavda, Jia-Nan Gong, David C. S. Huang, Asim Khwaja, Kwee Yong
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionBCL-2 family proteins are important for tumour cell survival and drug resistance in multiple myeloma (MM). Although proteasome inhibitors are effective anti-myeloma drugs, some patients are resistant and almost all eventually relapse. We
Externí odkaz:
https://doaj.org/article/3f533fcbf74447e289791076e3a6c8ea
Autor:
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free
Externí odkaz:
https://doaj.org/article/8e61c702b45741d49f7cd38053f87ec5
Autor:
Orla McCourt, Abigail Fisher, Joanne Land, Gita Ramdharry, Anna L Roberts, Georgios Bekris, Kwee Yong
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background The addition of qualitative methodology to randomised controlled trials evaluating complex interventions allows better understanding of contextualised factors and their potential influence on trial delivery and outcomes, as well a
Externí odkaz:
https://doaj.org/article/1ef8136fbd3c49168b6a4efaedff1e5c
Autor:
Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S14-S15 (2023)
Objective: Isatuximab (Isa, anti-CD38 monoclonal antibody) is approved in combination with carfilzomib (K) and dexamethasone (d), for relapsed multiple myeloma (MM) patients (pts) after ≥1 prior therapy. Final progression free survival (PFS) analys
Externí odkaz:
https://doaj.org/article/5bf335a963004c8aafd92c9904acdefe
Autor:
Hanyun Zhang, Khalid AbdulJabbar, Tami Grunewald, Ayse U. Akarca, Yeman Hagos, Faranak Sobhani, Catherine S.Y. Lecat, Dominic Patel, Lydia Lee, Manuel Rodriguez-Justo, Kwee Yong, Jonathan A. Ledermann, John Le Quesne, E. Shelley Hwang, Teresa Marafioti, Yinyin Yuan
Publikováno v:
EBioMedicine, Vol 95, Iss , Pp 104769- (2023)
Summary: Background: Efficient biomarker discovery and clinical translation depend on the fast and accurate analytical output from crucial technologies such as multiplex imaging. However, reliable cell classification often requires extensive annotati
Externí odkaz:
https://doaj.org/article/247dba90151c4cdeb67c905958d7c6d9
Autor:
Houfu Leng, Hanlin Zhang, Linsen Li, Shuhao Zhang, Yanping Wang, Selina J. Chavda, Daria Galas-Filipowicz, Hantao Lou, Adel Ersek, Emma V. Morris, Erdinc Sezgin, Yi-Hsuan Lee, Yunsen Li, Ana Victoria Lechuga-Vieco, Mei Tian, Jian-Qing Mi, Kwee Yong, Qing Zhong, Claire M. Edwards, Anna Katharina Simon, Nicole J. Horwood
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Here, the authors show that the glycosylceramide synthesis inhibitor and FDA approved drug Eliglustat inhibits autophagic degradation of TRAF3 which is a key step for osteoclast differentiation and thereby improves myeloma bone lesions.
Externí odkaz:
https://doaj.org/article/d3f4b2b671d34e5f9416142c53caf80d
Autor:
Hermann Einsele, Kwee Yong, Simon Harrison, Maria-Victoria Mateos, Philippe Moreau, Niels W.C.J. van de Donk, Surbhi Sidana, Rakesh Popat, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan Schecter, Katherine LI, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu-Min Yeh, Lida Pacaud, Nitin Patel, Binod Dhakal, Jesús San Miguel
Publikováno v:
HemaSphere, Vol 7, p e471416f (2023)
Externí odkaz:
https://doaj.org/article/34b535f5bfac4397bf4406c3214cc53f